# GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)

> **NCT05356104** · PHASE2 · RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 110 (estimated)

## Conditions studied

- Cerebral Small Vessel Disease

## Interventions

- **DRUG:** Exenatide extended release

## Key facts

- **NCT ID:** NCT05356104
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-25
- **Primary completion:** 2026-05
- **Final completion:** 2026-12
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05356104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05356104, "GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05356104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*